The relation between intellectual capital and intangible assets of pharmaceutical companies

The relation between intellectual capital and intangible assets of pharmaceutical companies Purpose – The purpose of this research is to assess the visibility of intangible assets on the balance‐sheet of pharmaceutical companies. Further, how these assets overlap with intellectual capital and whether a relation can be established between intangible assets and company performance. Design/methodology/approach – Intangible assets reporting practices of a group of 52 globally operating pharmaceutical companies are analysed. These assets are related to intellectual capital definitions and company performance. Findings – Results indicate that the majority of companies are specifying intangible assets and that a considerable overlap occurs with intellectual capital. Intangible assets may constitute substantially to the companies' assets. However, clear relations of intangible assets with company performance could not be established. Practical implications – Imperfections in the reporting of intangible assets are observed. These are the non‐uniformity of generally agreed accounting principles and practice around the world, the specification of goodwill and the position of R&D. A number of proposals are put forward to improve the visibility of intangible assets and to bring these in line with intellectual capital definitions. Originality/value – The value of the paper can be found in the approach to fulfil the ideal of intellectual capital valuation through the more practical way of intangible asset specification on the balance‐sheet. For the group of companies studied, this paper assesses the situation in 2003 and the way ahead to further improvement. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Intellectual Capital Emerald Publishing

The relation between intellectual capital and intangible assets of pharmaceutical companies

Journal of Intellectual Capital, Volume 7 (2): 13 – Apr 1, 2006

Loading next page...
 
/lp/emerald-publishing/the-relation-between-intellectual-capital-and-intangible-assets-of-vguliFtMGn
Publisher
Emerald Publishing
Copyright
Copyright © 2006 Emerald Group Publishing Limited. All rights reserved.
ISSN
1469-1930
DOI
10.1108/14691930610661881
Publisher site
See Article on Publisher Site

Abstract

Purpose – The purpose of this research is to assess the visibility of intangible assets on the balance‐sheet of pharmaceutical companies. Further, how these assets overlap with intellectual capital and whether a relation can be established between intangible assets and company performance. Design/methodology/approach – Intangible assets reporting practices of a group of 52 globally operating pharmaceutical companies are analysed. These assets are related to intellectual capital definitions and company performance. Findings – Results indicate that the majority of companies are specifying intangible assets and that a considerable overlap occurs with intellectual capital. Intangible assets may constitute substantially to the companies' assets. However, clear relations of intangible assets with company performance could not be established. Practical implications – Imperfections in the reporting of intangible assets are observed. These are the non‐uniformity of generally agreed accounting principles and practice around the world, the specification of goodwill and the position of R&D. A number of proposals are put forward to improve the visibility of intangible assets and to bring these in line with intellectual capital definitions. Originality/value – The value of the paper can be found in the approach to fulfil the ideal of intellectual capital valuation through the more practical way of intangible asset specification on the balance‐sheet. For the group of companies studied, this paper assesses the situation in 2003 and the way ahead to further improvement.

Journal

Journal of Intellectual CapitalEmerald Publishing

Published: Apr 1, 2006

Keywords: Intangible assets; Intellectual capital; Pharmaceuticals industry; Annual reports; Goodwill accounting

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off